Ligand Pharmaceuticals Inc (LGND)
R&D to Revenue
30.28%
Fiscal year · Period ending:
LGND R&D to Revenue
Latest reported30.28%period ending
Latest reported30.28%period ending
LGND FY R&D/Revenue (0.00% → 30.28%)
Latest values, visible window
High-resolution chart · PNG
LGND r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 30.282% | |
| 12.8191% | |
| 18.6857% | |
| 18.3862% | |
| 13.2916% | |
| 24.7631% | |
| 46.4808% | |
| 11.0808% | |
| 19.055% | |
| 19.4736% | |
| 18.6056% | |
| 18.7827% | |
| 18.9366% | |
| 34.3762% | |
| 34.2611% | |
| 93.7505% | |
| 102.3883% | |
| 112.6487% | |
| 346.0757% | |
| 29.7432% | |
| 31.7511% | |
| 39.8772% | |
| 47.9517% | |
| 60.8516% | |
| 66.9417% | |
| 106.6036% | |
| 145.2323% | |
| 399.435% | |
| 140.0387% | |
| 161.6848% | |
| 168.9796% | |
| 0% |